FDA's Rejection of Replimune's Drug Highlights Regulatory Consistency Concerns
The FDA has declined to approve Replimune's advanced melanoma drug for the second time, citing issues with the heterogeneity of the patient population in the clinical trials. This decision has sparked debate over the agency's regulatory flexibility and consistency. Replimune's CEO, Sushil Patel, criticized the FDA for not exercising regulatory flexibility to meet patient needs. The FDA's decision contrasts with the views of 22 scientists involved in the drug's trial, who argued that the patient diversity reflected real-world scenarios. The agency's decision-making process has been questioned for its lack of consistency, as highlighted by Peter Pitts, a former FDA associate commissioner. The FDA has recently issued new draft guidance for gene editing therapies to standardize safety assessments, aiming to balance safety with regulatory rigor. 
